

Siddhartha Devarakonda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8470600/publications.pdf>

Version: 2024-02-01

30
papers

1,531
citations

759233

12
h-index

642732

23
g-index

30
all docs

30
docs citations

30
times ranked

3100
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic alterations in lung adenocarcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e342-e351.	10.7	302
2	MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. <i>Cancer Cell</i> , 2020, 38, 60-78.e12.	16.8	262
3	Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2995-3006.	1.6	223
4	Clinical next-generation sequencing in patients with non-small cell lung cancer. <i>Cancer</i> , 2015, 121, 631-639.	4.1	190
5	Non-small-cell Lung Cancer With Brain Metastasis at Presentation. <i>Clinical Lung Cancer</i> , 2018, 19, e373-e379.	2.6	162
6	Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 3787.	12.8	112
7	Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1729-1735.	1.1	74
8	Overcoming Chemotherapy Resistance in SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2002-2015.	1.1	39
9	Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. <i>Journal of Clinical Oncology</i> , 2021, 39, 3747-3758.	1.6	38
10	Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 6119-6126.	7.0	28
11	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10 ⁺ advanced non-small cell lung cancer. , 2022, 10, e003581.		19
12	Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. <i>Cell Reports</i> , 2021, 34, 108707.	6.4	16
13	Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 543-549.	1.1	15
14	Next-Generation Sequencing of Lung Cancers. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 1-12.	2.2	12
15	A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. <i>Journal of Thoracic Disease</i> , 2021, 13, 4054-4062.	1.4	9
16	Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer. <i>Cancer Cell</i> , 2020, 38, 320-322.	16.8	5
17	Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 826-838.	2.8	5
18	Clonal Evolution: Multiregion Sequencing of Esophageal Adenocarcinoma Before and After Chemotherapy. <i>Cancer Discovery</i> , 2015, 5, 796-798.	9.4	4

#	ARTICLE	IF	CITATIONS
19	A phase 2 study of the MDM2 inhibitor milademetan in patients with <i>TP53</i> -wild type and <i>MDM2</i> -amplified advanced or metastatic solid tumors (MANTRA-2).. Journal of Clinical Oncology, 2022, 40, TPS3165-TPS3165.	1.6	4
20	Targeting Resistance to Targeted Therapies: Combating a Resilient Foe. Clinical Cancer Research, 2018, 24, 6112-6114.	7.0	3
21	278â€¦Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer. , 2020, 8, A303-A303.		3
22	Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 856132.	2.8	2
23	Biomarker-Driven Stagingâ€”Are We There Yet?. JAMA Network Open, 2019, 2, e1917052.	5.9	1
24	Prevalence, clinical risk factors and outcomes of patients with lung cancer presenting with brain metastases.. Journal of Clinical Oncology, 2016, 34, 2075-2075.	1.6	1
25	Adjuvant chemotherapy for patients with T2N0M0 non-small cell lung cancer.. Journal of Clinical Oncology, 2015, 33, 7520-7520.	1.6	1
26	Stage III pulmonary large cell neuroendocrine carcinoma (LNEC).. Journal of Clinical Oncology, 2016, 34, 8536-8536.	1.6	1
27	Use of chemotherapy for patients with stage IV non-small cell lung cancer.. Journal of Clinical Oncology, 2015, 33, e19010-e19010.	1.6	0
28	Prognostic and predictive effect of <i>KRAS</i> gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2020, 38, e21080-e21080.	1.6	0
29	Reply to G. Bi et al. Journal of Clinical Oncology, 2022, 40, 1260-1260.	1.6	0
30	Trends in stage I lung cancer.. Journal of Clinical Oncology, 2022, 40, 10508-10508.	1.6	0